A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline <em>BRCA1</em> or <em>BRCA2</em> m

Coleman, Robert

136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m

Tuesday, March 25, 2014: 7:36 AM

Ballroom B/C (Tampa Convention Center)

R. L. Coleman¹, M. Sill², C. Aghajanian³, H. J. Gray⁴, K. S. Tewari⁵, S. C. Rubin⁶, T. J. Rutherford⁷, J. K. Chan⁸, H. X. Chen⁹ and E. M. Swisher⁴
¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, ³Memorial Sloan Kettering Cancer Center, New York, NY, ⁴University of Washington Medical Center, Seattle, WA, ⁵University of California at Irvine, Irvine, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Yale University School of Medicine, New Haven, CT, ⁸UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, ⁹National Cancer Institute, Bethesda, MD

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m

136 - Scientific Plenary A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m

136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m